BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 19, 2025
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

IV insertion
AACR Virtual Meeting II

COVID-19 and cancer

June 29, 2020
By Brian Orelli
Multiple sessions at the American Association for Cancer Research Virtual Annual Meeting II covered how COVID-19 is affecting cancer patients, from how clinical trials needed to be modified during the pandemic to how real-world evidence can play a role now and in the future.
Read More

Week in review for June 22-26, 2020: Multispecific drugs opening a pathway to undruggable targets

June 29, 2020
By Peter Winter
A quick look back at top stories.
Read More
Dice spelling out D-E-A-L-?, yes, no

May deals dip, but Abbvie-Allergan M&A is fourth largest to date

June 26, 2020
By Karen Carey
Deals tracked by BioWorld indicate a slight slowdown in activity moving from April to May, showing an 8% drop in the number of deals and a 43% drop in the disclosed deal values.
Read More

Money raised by biopharma: 2020 vs. 2019

June 26, 2020
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-June 25, 2020

June 26, 2020
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Med-tech gainers and losers for June 22-26, 2020

June 26, 2020
The top 10 med-tech stock gainers and losers for the week.
Read More

Biggest gainers and losers for the week of June 22-26, 2020

June 26, 2020
The top 10 biopharma stock gainers and losers for the week.
Read More
Cells, DNA illustration

With $700M first round financing, privately held Sana slips into top spot

June 24, 2020
By Karen Carey
Up-and-coming cell and gene engineering company Sana Biotechnology Inc. raised $700 million in a first round financing, bumping Moderna Inc., which previously had the highest venture capital (VC) financing of a traditional biotech company to date.
Read More
Artificial intelligence and digital health icons

Artificial intelligence strategies being implemented by biopharma companies

June 23, 2020
By Peter Winter
The importance of artificial intelligence and machine learning continues to be acknowledged by drug development companies. Recently, to help accelerate the discovery of therapies to treat COVID-19, several deals have been forged to deploy those tools.
Read More
Drug research illustration
Sea change

Multispecific drugs opening a pathway to undruggable targets

June 22, 2020
By Peter Winter
In a BIO Digital session on “The Convergence of Health and Tech: Personalizing Medicine Beyond the Imaginable,” panelist Ray Deshaies, Amgen Inc.’s senior vice president of global research, said he was excited for the future of drug research, noting that there is an evolving trend away from the development of monospecific drugs designed to exert their effect on just one specific target.
Read More
Previous 1 2 … 218 219 220 221 222 223 224 225 226 … 264 265 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • Stock chart, upward arrow

    An early stage 85% remissions rate in AML drives Aptevo’s stock surge

    BioWorld
    An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing